Skip to content
OpenCapital
Get started

OrthoPediatrics KIDS Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Boston Scientific logo
Boston ScientificBSX
——

Other financials

Income statement

See full
Revenue$59.4M+13.3%
Gross profit$43.4M+13.4%
Operating income-$8.3M+24.1%
Net income-$10.7M-0.3%
EPS (diluted)-$0.45+2.2%

Balance sheet

See full
Cash & equivalents$14.2M-59.8%
Total debt$5.4M+271%
Total equity$338.7M-2.4%
Total assets$502.2M+6.8%

Cash flow

See full
Operating cash flow-$3.3M+20.9%
CapEx$1.8M-58.4%
Free cash flow-$5.0M+39.8%

Valuation

See full
Market cap$503.94M+0.3%
Enterprise value$495.11M+5.7%
P/S2.1×-0.3×

Profitability

See full
Gross margin73.1%+0.3pp
Operating margin-15%-1.6pp
Net margin-16.3%-2.1pp
FCF margin-12.9%-4.3pp

Returns & leverage

See full
Return on equity-11.6%+0.2pp
Debt / equity0×0.0×
Current ratio5.2×-1.0×

Where this comes from

Reported directly by OrthoPediatrics in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: OrthoPediatrics’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about OrthoPediatrics's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OrthoPediatrics's indefinite-lived research and development assets?
OrthoPediatrics (KIDS) reported indefinite-lived research and development assets of $12.91M in Q1 2026.
How has OrthoPediatrics's indefinite-lived research and development assets changed year-over-year?
OrthoPediatrics's indefinite-lived research and development assets decreased by 22.8% year-over-year, from $16.74M to $12.91M.
What is the long-term trend for OrthoPediatrics's indefinite-lived research and development assets?
Over 5 years (2020 to 2025), OrthoPediatrics's indefinite-lived research and development assets has grown at a -1.6% compound annual growth rate (CAGR), from $13.96M to $12.91M.